Posts Tagged ‘diagnostics’

Agilent makes investment in Lasergen

March 8th, 2016
Posted by


Agilent is investing $80 million in our client Lasergen, an emerging biotechnology company with innovative next-generation sequencing (NGS) technology. The two companies will collaborate on building a NGS solutions workflow for clinical applications, based on Lasergen’s Lightning Terminators™ sequencing chemistry.

This recent investment showcases the trend toward new players and innovative technology in the NGS space, particularly as the technology moves to more routine clinical use.

Lasergen’s relationship with Agilent is another example of how Popper and Company helps companies create transformative business partnerships.



Tags: , , ,
Posted in Diagnostics, Our Views | Comments Off on Agilent makes investment in Lasergen

Diversigen, Baylor Miraca Form Partnership

February 26th, 2016
Posted by



The recent partnership between Diversigen and Baylor Miraca Genetics highlights the importance of both human genetics and the microbiome in drug development and ultimately in clinical decision making.

We are in the early days of understanding the scope of the impact of the microbiome but we already know of powerful associations in diseases as diverse as inflammatory bowel disease, diabetes and cancer.

We are excited about this partnership as it leverages real technical and interpretive expertise across across a broad array of genomes relevant to human health.

Read more about their partnership.

Tags: , , , ,
Posted in biomedical research, Diagnostics | Comments Off on Diversigen, Baylor Miraca Form Partnership

Congratulations to Withings!

January 22nd, 2016
Posted by

Congratulations to our client, Withings, for being honored with the 2016 CES Innovation Awards in two categories, as well as being given the ‘Best of CES’ Awards from many major publications. Withings hit the press jackpot with their two latest innovations:
Read the rest of this entry »

Tags: , , , , , ,
Posted in Diagnostics, Digital health, Our News | Comments Off on Congratulations to Withings!

Single Cell Biology: A Step Toward Precision Diagnostics

January 21st, 2016
Posted by

The past several years have seen a dramatic increase in the ability to isolate and characterize single cells – leading to advances in diagnostics, drug discovery, stem cell biology, cancer, and many other areas of biomedical research.

These advances have arisen thanks to growing capabilities in various single cell “omics” technologies – which have enabled RNA and DNA sequencing on a genome-wide scale (the interrogation of proteins, metabolites, and many other types of molecules that provide information about cellular growth, differentiation, and the underlying molecular basis of disease).

And why has single cell technology become so attractive within the biomedical research community? Because most studies are currently hampered by sample heterogeneity.

Read the rest of this entry »

Tags: , , , , ,
Posted in biomedical research, Diagnostics, Our Views | 1 Comment »

Notes From Afield—#TEDMED, Day One

October 27th, 2011
Posted by

TEDMED, that health-focused meeting of the minds, is underway in San Diego, and I wanted to share some impressions of the ideas proposed at the conference. This week, there are a lot of very interesting exhibits, thoughtful presentations, and a bright, energetic audience here. And if there was a central theme to this year’s TEDMED, I’d say it was “redefinition;” rephrasing our questions to reflect what we’ve learned about how the natural, social, and physical worlds actually work.  I’d like you to chime in; share your thoughts with me on these ideas, or any others!
Here are some of my initial takeaways:


  1. Dr. David Agus of USC observed that the power of sophisticated diagnostics is needed to produce truly targeted personalized medicine, but wonders if we need to not only redefine diseases such as cancer, but also to find different, more useful definitions of health. In other words, should we focus on defining health, or instead focus on what is meant by disease?
  2. Ger Brophy of General Electric Healthcare focused on the theme of cancer on a personal basis, rather than on the geography of where the cancer is. As we’ve discussed via this blog, cancer’s traditional definitions based on anatomical location are not keeping up with what we know about the disease – and its many forms – today. Read the rest of this entry »

Tags: , , , , , , , ,
Posted in Events | Comments Off on Notes From Afield—#TEDMED, Day One

What You Need to Know About AdvaMed 2011

September 19th, 2011
Posted by

An Interview with AdvaMed Conference Producer Ray Briscuso
In preparation for AdvaMed 2011: The MedTech Conference, we had a unique opportunity to interview Ray Briscuso, President and CEO at Life Sciences Conference Group, LLC. Each year, Briscuso works with the Advanced Medical Technology Association (AdvaMed) to produce one of the most important meetings focused on medical devices and diagnostics, and which brings together more than 1,500 key MedTech executives from companies in every sector of the industry. It is the premier conference, exhibition and partnering event for medical device, diagnostic and health information companies. In the past, internationally respected voices, such as former Presidents George Bush (Sr.) and Bill Clinton, have been featured as plenary speakers.
I am eagerly anticipating September 26-28 when AdvaMed 2011 will be held in Washington, DC. Following are some insights and highlights from our discussion with Ray about how to get the most out of this year’s event: Read the rest of this entry »

Tags: , , , , , ,
Posted in Interviews | Comments Off on What You Need to Know About AdvaMed 2011

What FDA’s Proposed Drug Testing Guidelines May Mean for You

July 15th, 2011
Posted by

This week, the FDA issued draft guidance for in vitro companion diagnostics. After a day or so of reflecting about it, here’s what I think it may mean for you:
Overall, while the guidance itself may not be BIG news, it does seem to make good sense for business and to offer life science companies some flexibility. Whether you are a therapeutics company or a diagnostics company, you should see new opportunities as a result.
Following are the key points I took away from my review of the guidance:


  • The FDA acknowledges that not all co-development of diagnostic tests and therapeutic drugs can occur simultaneously. Thus, there is room for you to secure approval of a drug before the test is available and also to seek to modify the drug’s label as new diagnostics information emerges. There is also room for you to potentially market an as yet uncleared or unapproved test, if the marketing of the test is critical in the context of a drug. Read the rest of this entry »

Tags: , , , ,
Posted in Our Views | Comments Off on What FDA’s Proposed Drug Testing Guidelines May Mean for You

TRI-CON – Diagnostics, Drug Discovery & Biologics: Oh My!

February 21st, 2011
Posted by

Sometimes, between the hotel room, the lectures, the networking, the power lunches and the data consumption at a conference, you’re on the plane home before you have time to reflect upon why you attended in the first place. I’m excited to be heading to the 18th International Molecular Medicine Tri-Conference in San Francisco this week—and I’m setting out my reasons for going this year beforehand.
I always look forward to this conference because of its balanced range of life science topics, including those with technical, scientific, business, strategy, regulatory and reimbursement slants. Within this balanced range of topics, the Tri-Con uses a channel structure to help attendees “tune in” where they can get the biggest bang for their buck. I’m excited to learn more about the following specifics within each channel: Read the rest of this entry »

Tags: , , , , , , , , , , ,
Posted in Our News | Comments Off on TRI-CON – Diagnostics, Drug Discovery & Biologics: Oh My!